Overview

Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection

Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the bioequivalence of HS627(2 specifications) with PERJETA in a single intravenous administration in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Treatments:
Pertuzumab